Is Abbott Laboratories overvalued or undervalued?

As of 21 November 2025, the valuation grade for Abbott Laboratories has moved from very attractive to attractive. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 19, an EV to EBITDA of 25.84, and a PEG ratio of 0.14, indicating strong growth potential relative to its price.
In comparison to its peers, Abbott Laboratories has a more favorable P/E ratio of 18.36 compared to Thermo Fisher Scientific's 30.06 and Medtronic's 21.47, suggesting that it is priced more competitively within the industry. Despite a recent decline in stock price, Abbott has outperformed the S&P 500 year-to-date with a return of 12.45% compared to the index's 12.26%, although it has lagged significantly over the longer three and five-year periods.